Auswahl der wichtigsten Publikationen

  1. Liu SK, Bham SA, Fokas E, et al. Delta-like ligand 4-notch blockade and tumor radiation response. Journal of the National Cancer Institute 2011;103:1778-98.
  2. Fokas E, Im JH, Hill S, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Research 2012;72:239-48.
  3. Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. Journal of Clinical Oncology 2014;32:1554-62.
  4. Ashton TM, Fokas E, Kunz-Schughart LA, et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nature communications 2016;7:12308.
  5. Azad A, Yin Lim S, D'Costa Z,…., Fokas E. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Molecular Medicine 2017;9:167-80.
  6. Fokas E, Ströbel P, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer. Journal of the National Cancer Institute 2017. 2017;109(12). 
  7. D'Costa Z, Jones K, Azad A, van Stiphout R, Lim SY, …, Fokas E. Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. Cancer Research 2017;77(21):5952-5962.
  8. Kitz J*, Fokas E*, Beissbarth T, et al. The plane of total mesorectal excision is prognostic in rectal cancer: Results of the CAO/ARO/AIO-04 open-label, randomized, phase 3 trial. JAMA Surgery 2018, 153(8):e181607. *joint first authors.
  9. Fokas E, Fietkau R, Hartmann A, et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase 3 trial. Annals of Oncology 2018, 29(7):1521-1527.
  10. Hofheinz RD, Arnold D, Fokas E, et al. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Annals of Oncology 2018; 29(8): 1793-9.
  11. Fokas E, Allgauer M, Polat B, et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. Journal of Clinical Oncology 2019: JCO1900308.

Originalarbeiten

  1. Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncology reports 2008;19:151-6.
  2. Wang LF, Fokas E, Juricko J, You A, Rose F, Pagenstecher A, et al. Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC cancer 2008;8:79.
  3. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al] 2009;185:235-40.
  4. Xia P, An HX, Dang CX, Radpour R, Kohler C, Fokas E, et al. Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC cancer 2009;9:454.
  5. Fokas E, Hanze J, Kamlah F, Eul BG, Lang N, Keil B, et al. Irradiation-dependent effects on tumor perfusion and endogenous and exogenous hypoxia markers in an A549 xenograft model. Int J Radiat Oncol Biol Phys 2010;77:1500-8.
  6. Fokas E, Henzel M, Engenhart-Cabillic R. A comparison of radiotherapy with radiotherapy plus surgery for brain metastases from urinary bladder cancer: analysis of 62 patients. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al] 2010;186:565-71.
  7. Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al] 2010;186:210-7.
  8. He HT, Fokas E, You A, Engenhart-Cabillic R, An HX. Siah1 proteins enhance radiosensitivity of human breast cancer cells. BMC cancer 2010;10:403.
  9. Strassmann G, Abdellaoui S, Richter D, Bekkaoui F, Haderlein M, Fokas E, et al. Atlas-based semiautomatic target volume definition (CTV) for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2010;78:1270-6.
  10. Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R. Multidisciplinary treatment of brain metastases derived from colorectal cancer incorporating stereotactic radiosurgery: analysis of 78 patients. Clinical colorectal cancer 2011;10:121-5.
  11. Fokas E, You A, Juricko J, Engenhart-Cabillic R, An HX. Genetic alterations after carbon ion irradiation in human lung adenocarcinoma cells. International journal of oncology 2011;38:161-8.
  12. Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, et al. Delta-like ligand 4-notch blockade and tumor radiation response. Journal of the National Cancer Institute 2011;103:1778-98.
  13. Strassmann G, Olbert P, Hegele A, Richter D, Fokas E, Timmesfeld N, et al. Advantage of robotic needle placement on a prostate model in HDR brachytherapy. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al] 2011;187:367-72.
  14. You A, Fokas E, Wang LF, He H, Kleb B, Niederacher D, et al. Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer. J Cancer Res Clin Oncol 2011;137:621-7.
  15. Fokas E, Henzel M, Hamm K, Grund S, Engenhart-Cabillic R. Brain metastases in breast cancer: analysis of the role of HER2 status and treatment in the outcome of 94 patients. Tumori 2012;98:768-74.
  16. Fokas E, Henzel M, Surber G, Kleinert G, Hamm K, Engenhart-Cabillic R. Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. Journal of neuro-oncology 2012;109:91-8.
  17. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer research 2012;72:239-48.
  18. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell death & disease 2012;3:e441.
  19. Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, et al. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiation oncology 2012;7:48.
  20. Prevo R*, Fokas E*, Reaper PM, Charlton PA, Pollard JR, McKenna WG, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer biology & therapy 2012;13:1072-81. (joint first author)
  21. Balermpas P, Michel Y, Wagenblast J, Seitz O, Sipek F, Rödel F,…., Fokas E. Nuclear NF-kappaB expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy. Int J Radiat Oncol Biol Phys 2013;86:785-90.
  22. Fokas E, Conradi L, Weiss C, Sprenger T, Middel P, Rau T, et al. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study. Int J Radiat Oncol Biol Phys 2013;87:992-9.
  23. Fokas E, Eccles C, Patel N, Chu KY, Warren S, Gillies McKenna W, et al. Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al] 2013;189:407-16.
  24. Fokas E, Eccles C, Patel N, Chu KY, Warren S, McKenna WG, et al. A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy. Radiother Oncol 2013;107:200-6.
  25. Fokas E, Henzel M, Wittig A, Grund S, Engenhart-Cabillic R. Stereotactic radiosurgery of cerebral arteriovenous malformations: long-term follow-up in 164 patients of a single institution. Journal of neurology 2013;260:2156-62.
  26. Henzel M, Fokas E, Sitter H, Wittig A, Engenhart-Cabillic R. Quality of life after stereotactic radiotherapy for meningioma: a prospective non-randomized study. Journal of neuro-oncology 2013;113:135-41.
  27. Warren S, Partridge M, Fokas E, Eccles CL, Brunner TB. Comparing dose-volume histogram and radiobiological endpoints for ranking intensity-modulated arc therapy and 3D-radiotherapy treatment plans for locally-advanced pancreatic cancer. Acta oncologica 2013;52:1573-8.
  28. Balermpas P, Bauer C, Fraunholz I, Ottinger A, Wagenblast J, Stover T, Fokas E, et al. Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al] 2014;190:256-62.
  29. Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rödel F,…., Fokas E. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. British journal of cancer 2014;110:501-9.
  30. Balermpas P, Rödel F, Liberz R, Oppermann J, Wagenblast J, Ghanaati S,…, Fokas E. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. British journal of cancer 2014;111:1509-18.
  31. Balermpas P, Rödel F, Weiss C, Rödel C, Fokas E. Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology 2014;3:e27403.
  32. Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R. Stereotactic radiotherapy of benign meningioma in the elderly: clinical outcome and toxicity in 121 patients. Radiother Oncol 2014;111:457-62.
  33. Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R. Stereotactic radiation therapy for benign meningioma: long-term outcome in 318 patients. Int J Radiat Oncol Biol Phys 2014;89:569-75.
  34. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014;32:1554-62.
  35. Kelly CJ, Hussien K, Fokas E, Kannan P, Shipley RJ, Ashton TM, et al. Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia. Radiother Oncol 2014;111:72-80.
  36. Fokas E, Clifford C, Spezi E, Joseph G, Branagan J, Hurt C, et al. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiother Oncol 2015;117:432-7.
  37. Fokas E, Liersch T, Fietkau R, Hohenberger W, Hess C, Becker H, et al. Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: the reverse of the Will Rogers phenomenon? Cancer 2015;121:1724-7.
  38. Huang X, Taeb S, Jahangiri S, Korpela E, Cadonic I, Yu N, Fokas E, et al. miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). Oncotarget 2015;6:22439-51.
  39. Rödel F, Wieland U, Fraunholz I, Kitz J, Rave-Frank M, Wolff HA,…., Fokas E, Rödel C. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. International journal of cancer 2015;136:278-88.
  40. Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nature communications 2016;7:12308.
  41. Balermpas P, Rödel F, Rödel C, Krause M, Linge A, Lohaus F,…, Fokas E. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). International journal of cancer 2016;138:171-81.
  42. Diana A, Wang LM, D'Costa Z, Allen P, Azad A, Silva MA,…, Fokas E. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:40992-1004.
  43. Diana A, Wang LM, D'Costa Z, Azad A, Silva MA, Soonawalla Z,…, Fokas E. Prognos